Perseus Proteomics Income Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Revenue	140.41	120	100	94	71	67
Revenue Growth (YoY)	26.06%	20.00%	6.38%	32.39%	5.97%	-21.18%
Cost of Revenue	19.36	16	13	7	5	4
Gross Profit	121.05	104	87	87	66	63
Selling, General & Admin	899.99	336	366	290	231	162
Research & Development	-9.25	594	616	494	308	313
Operating Expenses	890.74	930	982	784	539	475
Operating Income	-769.69	-826	-895	-697	-473	-412
Interest & Investment Income	4.64	1	-	-	-	-
Currency Exchange Gain (Loss)	-1.7	-2	16	7	9	1
Other Non Operating Income (Expenses)	51.82	-3	-1	-	-19	-
EBT Excluding Unusual Items	-714.93	-830	-880	-690	-483	-411
Asset Writedown	-41.13	-72	-153	-95	-117	-1
Other Unusual Items	-	-	-70	-	2	-
Pretax Income	-756.06	-902	-1,103	-785	-598	-412
Income Tax Expense	2.06	2	1	1	1	1
Net Income	-758.12	-904	-1,104	-786	-599	-413
Net Income to Common	-758.12	-904	-1,104	-786	-599	-413
Shares Outstanding (Basic)	15	14	12	12	11	7
Shares Outstanding (Diluted)	15	14	12	12	11	7
Shares Change (YoY)	0.03%	21.05%	0.24%	6.94%	57.10%	13.88%
EPS (Basic)	-51.41	-63.35	-93.65	-66.84	-54.47	-59.00
EPS (Diluted)	-51.41	-63.35	-93.65	-66.84	-54.47	-59.00
Free Cash Flow	-	-794	-976	-728	-509	-424
Free Cash Flow Per Share	-	-55.65	-82.80	-61.91	-46.29	-60.57
Gross Margin	86.21%	86.67%	87.00%	92.55%	92.96%	94.03%
Operating Margin	-548.18%	-688.33%	-895.00%	-741.49%	-666.20%	-614.93%
Profit Margin	-539.94%	-753.33%	-1104.00%	-836.17%	-843.66%	-616.42%
Free Cash Flow Margin	-	-661.67%	-976.00%	-774.47%	-716.90%	-632.84%
EBITDA	-	-824	-892	-692	-471	-
D&A For EBITDA	1.25	2	3	5	2	-
EBIT	-769.69	-826	-895	-697	-473	-412

Source: S&P Global Market Intelligence. Standard template. Financial Sources.